Eli Lilly and Company

Activity in this selectionOct 7, 2026 · Jul 10, 2026

By stage

Series A2

Series B2

Series C+2

Biotech6

United States5

Australia1

6 in this selection

Aug 17

Develops neuro-metabolic therapeutics for schizophrenia and ALS

$30MSeries A

Role not disclosed

Aug 12

Clinical-stage biopharma developing injectable therapies for hair loss

$26MSeries B

Role not disclosed

Aug 12

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

$77MSeries B

Role not disclosed

Aug 10

Develops durable protein therapeutics via gene therapy for chronic diseases

$10MSeries A

Role not disclosed

Jul 31

Developing best-in-class radiopharmaceuticals for cancer treatment

$70MSeries C

Role not disclosed

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed